EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities

Linling Yang, Parastoo Akbarabadi, Sadegh Babashah

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026

DOI: 10.1016/j.bbcan.2026.189545 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Linling Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Exosomes, Cancer-Associated Fibroblasts, Colorectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 201 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) progression is profoundly shaped by the tumor microenvironment. Among stromal components, cancer-associated fibroblasts (CAFs) release small extracellular vesicles (exosomes) that deliver miRNAs, lncRNAs, circRNAs, proteins, and metabolites to malignant and immune cells. In CRC, CAF-derived exosomes (CAF-Exo) drive epithelial-mesenchymal transition, sustain stemness, stimulate angiogenesis, suppress antitumor immunity, and promote resistance to fluoropyrimidines and oxaliplatin. Representative mechanisms include exosomal miR-92a-3p activation of Wnt/β-catenin signaling, the lncRNA WEE2-AS1-mediated suppression of Hippo restraint with YAP activation, and circRNA cargos that reprogram autophagy or endothelial dynamics. Circulating CAF-Exo signatures are emerging as minimally invasive biomarkers for diagnosis, prognosis, and therapy stratification. However, translation remains limited by CAF heterogeneity, cargo variability, and incomplete in vivo characterization of vesicle dynamics. Therapeutic opportunities include blockade of exosome biogenesis or uptake, pharmacologic reprogramming of CAFs, and engineering vesicles to deliver targeted inhibitors or RNA-based therapeutics. This review synthesizes current mechanistic insights, evaluates biomarker potential, and outlines clinical priorities for targeting CAF-exosomal pathways in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesCancer-Associated FibroblastsColorectal NeoplasmsHumansTumor MicroenvironmentDisease ProgressionAnimalsBiomarkers, TumorEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

BiomarkersCancer-associated fibroblastsColorectal cancerExosomesNon-coding RNAsTumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
  • Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
  • Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: Babashah@modares.ac.ir.

Zitieren

APA

Yang, L., Akbarabadi, P., & Babashah, S. (2026). Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2026.189545

Vancouver

Yang L, Akbarabadi P, Babashah S. Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2026.189545

BibTeX
@article{Yang2026,
  author = {Yang, Linling and Akbarabadi, Parastoo and Babashah, Sadegh},
  title = {Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  doi = {10.1016/j.bbcan.2026.189545}
}
Kostenlos starten →